fbpx
Wikipedia

Dilute Russell's viper venom time

Dilute Russell's viper venom time (dRVVT) is a laboratory test often used for detection of lupus anticoagulant (LA). It is an assessment of the time for blood to clot in the presence of a diluted amount of venom from Russell's viper (Daboia russelii), a highly venomous snake native to the Indian subcontinent and named after the herpetologist Patrick Russell.[1]

Russell's viper, Daboia russelii

History edit

Russell's viper venom (RVV) was known to clot blood many years ago.[2] It was widely used as a styptic to clot minor wounds when razor blades were more commonly used for shaving (e.g. “Stypven”, Burroughs-Wellcome Pharma). RVV came to be useful in laboratory tests for blood clotting factors V, X, prothrombin and phospholipid.[3]

It was first used in clotting tests for lupus anticoagulant (LA) in an individual case in 1975.[4] The “dilute Russells Viper Venom time (dRVVT)” test was then applied in 1985 to diagnose LA in a large number of patients and it became more widely used for this purpose. This multi-step method involved adding individual solutions of dilute phospholipid, RVV and calcium chloride to a test plasma and then measuring how long it took for the mixture to clot.[5]

In 1989, researchers at Westmead Hospital developed a simpler assay by combining the venom, phospholipid, and calcium into a single reagent. Its first use on LA patients was reported in 1990.[6] It was commercialized as “LA Screen” by Gradipore Ltd, Sydney (later Life Diagnostics) and distributed widely by American Diagnostica Inc (New York) as “dVVTest”.

The reagent was improved in 1992 by making it resistant to the widely used interfering anticoagulant heparin. Also a new LA resistant version with increased phospholipid was released at that time. This was introduced as “LA-Confirm” by Gradipore and “dVVConfirm” by American Diagnostica. Results with this high phospholipid reagent were not prolonged by most LA but remained similarly affected as in the "screen" test by all other variables in test plasmas (Gradipore product information). The combination of screening and confirmatory dRVVT reagents made identification of LA more simple.[7] Manufacture of these reagents has since passed on to the major diagnostic companies such as Diagnostica Stago, Precision Biologic, and IL/Werfen.

Mechanism edit

The dRVVT assay relies on the venom of the Russelli viper. The venom contains enzymes (RVV-X) that directly activates clotting factor X (bypassing intrinsic and extrinsic cascades).[8] In the presence of calcium and phospholipids, these factors convert prothrombin into thrombin, leading to fibrin clot formation. The assay uses low concentrations of venom and phospholipids, resulting in a standard clotting time of 35 to 37 seconds. The test has three phases: In screening phase a lower phospholipid quantity is used (35–37 seconds clotting time) to enhance sensitivity to lupus anticoagulant.[9] In confirmatory phase full phospholipid dose (30–35 seconds clotting time) helps validate results. In mixing Study, the Patient plasma is mixed with normal pooled plasma (NPP) in1:1 ratio to assess clotting factor deficiency. If clotting time prolongs during screening, lupus antibodies may be present. Mixing study differentiates between lupus antibodies and factor deficiency. Excess phospholipids in the confirmatory phase shorten clotting time if lupus antibodies are present.[10]

Interpretation edit

Through the three phases, following ratios are calculated which help interpret the diagnosis:

i) dRVVT Screen Ratio: Patient plasma dRVVT/NPP dRVVT

ii) dRVVT Confirm Ratio (Phospholipid Neutralization): Patient confirm dRVVT/NPP confirm dRVVT

iii) Normalized Phospholipid Neutralization Ratio: dRVVT screen ratio/dRVVT confirm ratio

iv) dRVVT Mix Ratio: (Patient plasma + NPP mix dRVVT)/(NPP dRVVT)

dRVVT Interpretation/Algorithm
dRVVT Screen Ratio Normalized Phospholipid Neutralization ratio dRVVT Mix Ratio Interpretation
<1.2 Not Tested Not Tested Negative
≥1.2 ≥1.2 Not tested Probable Lupus Anticoagulant
≥1.2 <1.2 <1.20 Possible factor deficiency or anticoagulant therapy
≥1.2 <1.2 ≥1.2 Possible Factor inhibitor or anticoagulation therapy

Additional calculations are made using percentage correction of dRVVT and Normalizaed percentage correction as under:

i) Percentage correction = [Patient Screen dRVVT/Patient confirm dRVVT] x 100

ii) Normalized percentage correction = [(dRVVT Screen Ratio - dRVVT confirm ratio) /dRVVT screen ratio] x 100 [11]

Normalized percentage correction of >10% is taken as positive and suggests the presence of Lupus anticoagulant.[11]

Limitations edit

However dRVVT tests are strongly affected by the new direct oral anticoagulants (DOACs) and false positive LA results are obtained particularly with rivaroxaban.[12] It is now possible to specifically remove DOACs from test plasmas with activated carbon and enable the correct diagnosis of LA with the dRVVT system despite their initial presence.[13]

Use in diagnosis edit

The dRVVT is one component of a workup of a suspected antiphospholipid antibody, the other component being the serological testing for anticardiolipin antibodies and anti-β2 glycoprotein-I antibodies using ELISA technology. The Sapporo criteria require at least one of the above laboratory tests to be positive and the patient to have at least one clinical manifestation of antiphospholipid syndrome, such as vascular thrombosis or fetal mortality/morbidity, in order to diagnose the antiphospholipid syndrome.[14] Positive laboratory test results should be seen on two occasions at least 12 weeks apart in order for diagnosis. Antiphospholipid antibody syndrome is an important marker for recurrent thrombosis, and often warrants indefinite anticoagulant (blood thinner) therapy. Warfarin appears to be preferable to DOACs as the latter have recently been found less effective than expected.[15]

The criteria were defined in 1999, and revised in 2006.[16]

References edit

  1. ^ Favaloro EJ (4 August 2019). "The Russell viper venom time (RVVT) test for investigation of lupus anticoagulant (LA)". American Journal of Hematology. 94 (11): 1290–1296. doi:10.1002/ajh.25606. PMID 31379004. S2CID 199438687.
  2. ^ Macfarlane RG (July 1967). "Russell's viper venom, 1934-64". British Journal of Haematology. 13 (4): 437–51. doi:10.1111/j.1365-2141.1967.tb00754.x. PMID 6067638. S2CID 2208466.
  3. ^ Marsh NA (July 1998). "Use of snake venom fractions in the coagulation laboratory". Blood Coagulation & Fibrinolysis. 9 (5): 395–404. doi:10.1097/00001721-199807000-00001. PMID 9712287.
  4. ^ Exner T, Rickard KA, Kronenberg H (October 1975). "Studies on phospholipids in the action of a lupus coagulation inhibitor". Pathology. 7 (4): 319–28. doi:10.3109/00313027509081688. PMID 1223721. S2CID 24552164.
  5. ^ Thiagarajan P, Pengo V, Shapiro SS (October 1986). "The use of the dilute Russell viper venom time for the diagnosis of lupus anticoagulants". Blood. 68 (4): 869–74. doi:10.1182/blood.V68.4.869.869. PMID 3092888.
  6. ^ Exner T, Papadopoulos G, Koutts J (August 1990). "Use of a simplified dilute Russell's viper venom time (DRVVT) confirms heterogeneity among 'lupus anticoagulants'". Blood Coagulation & Fibrinolysis. 1 (3): 259–66. doi:10.1097/00001721-199008000-00002. PMID 2129412.
  7. ^ Laboratory testing for the lupus anticoagulant : approved guideline. Clinical and Laboratory Standards Institute. 2014. ISBN 978-1-56238-959-8.
  8. ^ Castro-Amorim J, Oliveira A, Mukherjee AK, Ramos MJ, Fernandes PA (2023-07-10). "Unraveling the Reaction Mechanism of Russell's Viper Venom Factor X Activator: A Paradigm for the Reactivity of Zinc Metalloproteinases?". Journal of Chemical Information and Modeling. 63 (13): 4056–4069. doi:10.1021/acs.jcim.2c01156. ISSN 1549-9596. PMC 10336966. PMID 37092784.
  9. ^ Hillarp A, Strandberg K, Gustafsson KM, Lindahl TL (August 2020). "Unveiling the complex effects of direct oral anticoagulants on dilute Russell's viper venom time assays". Journal of Thrombosis and Haemostasis. 18 (8): 1866–1873. doi:10.1111/jth.14829.
  10. ^ Vandevelde A, Devreese KM (2022-04-13). "Laboratory Diagnosis of Antiphospholipid Syndrome: Insights and Hindrances". Journal of Clinical Medicine. 11 (8): 2164. doi:10.3390/jcm11082164. ISSN 2077-0383. PMC 9025581. PMID 35456258.
  11. ^ a b Moore GW (March 2014). "Recent Guidelines and Recommendations for Laboratory Detection of Lupus Anticoagulants". Seminars in Thrombosis and Hemostasis. 40 (2): 163–171. doi:10.1055/s-0033-1364185. ISSN 0094-6176. PMID 24500573.
  12. ^ Flieder T, Weiser M, Eller T, Dittrich M, von Bargen K, Alban S, Kuhn J, Knabbe C, Birschmann I (May 2018). "Interference of DOACs in different DRVVT assays for diagnosis of lupus anticoagulants". Thrombosis Research. 165: 101–106. doi:10.1016/j.thromres.2018.03.009. PMID 29627719.
  13. ^ Favaloro EJ, Gilmore G, Arunachalam S, Mohammed S, Baker R (August 2019). "Neutralising rivaroxaban induced interference in laboratory testing for lupus anticoagulant (LA): A comparative study using DOAC Stop and andexanet alfa" (PDF). Thrombosis Research. 180: 10–19. doi:10.1016/j.thromres.2019.05.013. PMID 31158643. S2CID 174807712.
  14. ^ Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, Derksen RH, De Groot PG, et al. (2006). "International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)". Journal of Thrombosis and Haemostasis. 4 (2): 295–306. doi:10.1111/j.1538-7836.2006.01753.x. hdl:11379/21509. PMID 16420554. S2CID 9752817.
  15. ^ Kajy M, Mathew A, Ramappa P (9 October 2019). "Treatment Failures of Direct Oral Anticoagulants". American Journal of Therapeutics. 28 (1): e87–e95. doi:10.1097/MJT.0000000000001083. PMID 31599766. S2CID 204029056.
  16. ^ Kaul M, Erkan D, Sammaritano L, Lockshin MD (July 2007). "Assessment of the 2006 revised antiphospholipid syndrome classification criteria". Ann. Rheum. Dis. 66 (7): 927–30. doi:10.1136/ard.2006.067314. PMC 2497429. PMID 17337473.

dilute, russell, viper, venom, time, drvvt, laboratory, test, often, used, detection, lupus, anticoagulant, assessment, time, blood, clot, presence, diluted, amount, venom, from, russell, viper, daboia, russelii, highly, venomous, snake, native, indian, subcon. Dilute Russell s viper venom time dRVVT is a laboratory test often used for detection of lupus anticoagulant LA It is an assessment of the time for blood to clot in the presence of a diluted amount of venom from Russell s viper Daboia russelii a highly venomous snake native to the Indian subcontinent and named after the herpetologist Patrick Russell 1 Russell s viper Daboia russelii Contents 1 History 2 Mechanism 3 Interpretation 4 Limitations 5 Use in diagnosis 6 ReferencesHistory editRussell s viper venom RVV was known to clot blood many years ago 2 It was widely used as a styptic to clot minor wounds when razor blades were more commonly used for shaving e g Stypven Burroughs Wellcome Pharma RVV came to be useful in laboratory tests for blood clotting factors V X prothrombin and phospholipid 3 It was first used in clotting tests for lupus anticoagulant LA in an individual case in 1975 4 The dilute Russells Viper Venom time dRVVT test was then applied in 1985 to diagnose LA in a large number of patients and it became more widely used for this purpose This multi step method involved adding individual solutions of dilute phospholipid RVV and calcium chloride to a test plasma and then measuring how long it took for the mixture to clot 5 In 1989 researchers at Westmead Hospital developed a simpler assay by combining the venom phospholipid and calcium into a single reagent Its first use on LA patients was reported in 1990 6 It was commercialized as LA Screen by Gradipore Ltd Sydney later Life Diagnostics and distributed widely by American Diagnostica Inc New York as dVVTest The reagent was improved in 1992 by making it resistant to the widely used interfering anticoagulant heparin Also a new LA resistant version with increased phospholipid was released at that time This was introduced as LA Confirm by Gradipore and dVVConfirm by American Diagnostica Results with this high phospholipid reagent were not prolonged by most LA but remained similarly affected as in the screen test by all other variables in test plasmas Gradipore product information The combination of screening and confirmatory dRVVT reagents made identification of LA more simple 7 Manufacture of these reagents has since passed on to the major diagnostic companies such as Diagnostica Stago Precision Biologic and IL Werfen nbsp Algorithm for LA testing with dRVVT screen and confirm reagentsMechanism editThe dRVVT assay relies on the venom of the Russelli viper The venom contains enzymes RVV X that directly activates clotting factor X bypassing intrinsic and extrinsic cascades 8 In the presence of calcium and phospholipids these factors convert prothrombin into thrombin leading to fibrin clot formation The assay uses low concentrations of venom and phospholipids resulting in a standard clotting time of 35 to 37 seconds The test has three phases In screening phase a lower phospholipid quantity is used 35 37 seconds clotting time to enhance sensitivity to lupus anticoagulant 9 In confirmatory phase full phospholipid dose 30 35 seconds clotting time helps validate results In mixing Study the Patient plasma is mixed with normal pooled plasma NPP in1 1 ratio to assess clotting factor deficiency If clotting time prolongs during screening lupus antibodies may be present Mixing study differentiates between lupus antibodies and factor deficiency Excess phospholipids in the confirmatory phase shorten clotting time if lupus antibodies are present 10 Interpretation editThrough the three phases following ratios are calculated which help interpret the diagnosis i dRVVT Screen Ratio Patient plasma dRVVT NPP dRVVTii dRVVT Confirm Ratio Phospholipid Neutralization Patient confirm dRVVT NPP confirm dRVVTiii Normalized Phospholipid Neutralization Ratio dRVVT screen ratio dRVVT confirm ratioiv dRVVT Mix Ratio Patient plasma NPP mix dRVVT NPP dRVVT dRVVT Interpretation Algorithm dRVVT Screen Ratio Normalized Phospholipid Neutralization ratio dRVVT Mix Ratio Interpretation lt 1 2 Not Tested Not Tested Negative 1 2 1 2 Not tested Probable Lupus Anticoagulant 1 2 lt 1 2 lt 1 20 Possible factor deficiency or anticoagulant therapy 1 2 lt 1 2 1 2 Possible Factor inhibitor or anticoagulation therapy Additional calculations are made using percentage correction of dRVVT and Normalizaed percentage correction as under i Percentage correction Patient Screen dRVVT Patient confirm dRVVT x 100ii Normalized percentage correction dRVVT Screen Ratio dRVVT confirm ratio dRVVT screen ratio x 100 11 Normalized percentage correction of gt 10 is taken as positive and suggests the presence of Lupus anticoagulant 11 Limitations editHowever dRVVT tests are strongly affected by the new direct oral anticoagulants DOACs and false positive LA results are obtained particularly with rivaroxaban 12 It is now possible to specifically remove DOACs from test plasmas with activated carbon and enable the correct diagnosis of LA with the dRVVT system despite their initial presence 13 Use in diagnosis editThe dRVVT is one component of a workup of a suspected antiphospholipid antibody the other component being the serological testing for anticardiolipin antibodies and anti b2 glycoprotein I antibodies using ELISA technology The Sapporo criteria require at least one of the above laboratory tests to be positive and the patient to have at least one clinical manifestation of antiphospholipid syndrome such as vascular thrombosis or fetal mortality morbidity in order to diagnose the antiphospholipid syndrome 14 Positive laboratory test results should be seen on two occasions at least 12 weeks apart in order for diagnosis Antiphospholipid antibody syndrome is an important marker for recurrent thrombosis and often warrants indefinite anticoagulant blood thinner therapy Warfarin appears to be preferable to DOACs as the latter have recently been found less effective than expected 15 The criteria were defined in 1999 and revised in 2006 16 References edit Favaloro EJ 4 August 2019 The Russell viper venom time RVVT test for investigation of lupus anticoagulant LA American Journal of Hematology 94 11 1290 1296 doi 10 1002 ajh 25606 PMID 31379004 S2CID 199438687 Macfarlane RG July 1967 Russell s viper venom 1934 64 British Journal of Haematology 13 4 437 51 doi 10 1111 j 1365 2141 1967 tb00754 x PMID 6067638 S2CID 2208466 Marsh NA July 1998 Use of snake venom fractions in the coagulation laboratory Blood Coagulation amp Fibrinolysis 9 5 395 404 doi 10 1097 00001721 199807000 00001 PMID 9712287 Exner T Rickard KA Kronenberg H October 1975 Studies on phospholipids in the action of a lupus coagulation inhibitor Pathology 7 4 319 28 doi 10 3109 00313027509081688 PMID 1223721 S2CID 24552164 Thiagarajan P Pengo V Shapiro SS October 1986 The use of the dilute Russell viper venom time for the diagnosis of lupus anticoagulants Blood 68 4 869 74 doi 10 1182 blood V68 4 869 869 PMID 3092888 Exner T Papadopoulos G Koutts J August 1990 Use of a simplified dilute Russell s viper venom time DRVVT confirms heterogeneity among lupus anticoagulants Blood Coagulation amp Fibrinolysis 1 3 259 66 doi 10 1097 00001721 199008000 00002 PMID 2129412 Laboratory testing for the lupus anticoagulant approved guideline Clinical and Laboratory Standards Institute 2014 ISBN 978 1 56238 959 8 Castro Amorim J Oliveira A Mukherjee AK Ramos MJ Fernandes PA 2023 07 10 Unraveling the Reaction Mechanism of Russell s Viper Venom Factor X Activator A Paradigm for the Reactivity of Zinc Metalloproteinases Journal of Chemical Information and Modeling 63 13 4056 4069 doi 10 1021 acs jcim 2c01156 ISSN 1549 9596 PMC 10336966 PMID 37092784 Hillarp A Strandberg K Gustafsson KM Lindahl TL August 2020 Unveiling the complex effects of direct oral anticoagulants on dilute Russell s viper venom time assays Journal of Thrombosis and Haemostasis 18 8 1866 1873 doi 10 1111 jth 14829 Vandevelde A Devreese KM 2022 04 13 Laboratory Diagnosis of Antiphospholipid Syndrome Insights and Hindrances Journal of Clinical Medicine 11 8 2164 doi 10 3390 jcm11082164 ISSN 2077 0383 PMC 9025581 PMID 35456258 a b Moore GW March 2014 Recent Guidelines and Recommendations for Laboratory Detection of Lupus Anticoagulants Seminars in Thrombosis and Hemostasis 40 2 163 171 doi 10 1055 s 0033 1364185 ISSN 0094 6176 PMID 24500573 Flieder T Weiser M Eller T Dittrich M von Bargen K Alban S Kuhn J Knabbe C Birschmann I May 2018 Interference of DOACs in different DRVVT assays for diagnosis of lupus anticoagulants Thrombosis Research 165 101 106 doi 10 1016 j thromres 2018 03 009 PMID 29627719 Favaloro EJ Gilmore G Arunachalam S Mohammed S Baker R August 2019 Neutralising rivaroxaban induced interference in laboratory testing for lupus anticoagulant LA A comparative study using DOAC Stop and andexanet alfa PDF Thrombosis Research 180 10 19 doi 10 1016 j thromres 2019 05 013 PMID 31158643 S2CID 174807712 Miyakis S Lockshin MD Atsumi T Branch DW Brey RL Cervera R Derksen RH De Groot PG et al 2006 International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome APS Journal of Thrombosis and Haemostasis 4 2 295 306 doi 10 1111 j 1538 7836 2006 01753 x hdl 11379 21509 PMID 16420554 S2CID 9752817 Kajy M Mathew A Ramappa P 9 October 2019 Treatment Failures of Direct Oral Anticoagulants American Journal of Therapeutics 28 1 e87 e95 doi 10 1097 MJT 0000000000001083 PMID 31599766 S2CID 204029056 Kaul M Erkan D Sammaritano L Lockshin MD July 2007 Assessment of the 2006 revised antiphospholipid syndrome classification criteria Ann Rheum Dis 66 7 927 30 doi 10 1136 ard 2006 067314 PMC 2497429 PMID 17337473 Retrieved from https en wikipedia org w index php title Dilute Russell 27s viper venom time amp oldid 1222486059, wikipedia, wiki, book, books, library,

article

, read, download, free, free download, mp3, video, mp4, 3gp, jpg, jpeg, gif, png, picture, music, song, movie, book, game, games.